Watchlist Price Alert

Elevation Oncology Inc. (ELEV)

NASDAQ: ELEV · Real-Time Price · USD

0.30

-0.01 (-1.99%)

At close: May 30, 2025, 3:59 PM

0.30

-0.03%

After-hours: May 30, 2025, 05:08 PM EDT

-1.99% (1D)

Bid	0.29
Market Cap	17.77M
Revenue (ttm)	n/a
Net Income (ttm)	-47.99M
EPS (ttm)	-0.81
PE Ratio (ttm)	-0.37
Forward PE	-0.73
Analyst	Hold

Ask	0.32
Volume	437,563
Avg. Volume (20D)	1,357,467
Open	0.31
Previous Close	0.31
Day's Range	0.30 - 0.31
52-Week Range	0.22 - 4.33
Beta	1.61

About ELEV

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ELEV

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ELEV stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

-12.24%

Elevation Oncology shares are trading lower after ... Unlock content with Pro Subscription

2 months ago

-41.82%

Elevation Oncology shares are trading lower after the company announced the discontinued development of EO-3021.

News

2 months ago · zacks.com

Elevation Oncology Plunges 42% on Ending Development of Lead Drug

ELEV decides to stop developing its lead drug after disappointing data from an early-stage study evaluating its sole clinical-stage drug in gastric cancers.

2 months ago · benzinga.com

Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%

On Thursday, Elevation Oncology, Inc. ELEV elected to discontinue the development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC).